David Cipolla, PhD, has >25 years of experience with a focus on the development of formulation and drug delivery technologies to support pharma product development. Dr Cipolla is Vice-President, Research at Insmed, where he is part of a team developing novel, targeted therapies to help serve the critical unmet needs of patients battling serious rare diseases. Prior to joining Insmed in 2018, he was Vice-President, Preclinical Research at Aradigm covering all phases of product development and before that he worked at Genentech developing and characterising the delivery of protein aerosols to the airways, culminating with the approval of Pulmozyme® rhDNase for the management of cystic fibrosis in 1993. Cipolla holds a chemical engineering degree from MIT (SB) and UC Davis (MS) and a pharmacy degree from the University of Sydney (PhD). He served as chair of IPAC-RS, chair of the ISAM Regulatory Affairs Working Group and ISAM Board Member.